nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—peripheral nervous system neoplasm	0.495	1	CbGaD
Linagliptin—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0614	0.167	CbGbCtD
Linagliptin—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0614	0.167	CbGbCtD
Linagliptin—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0425	0.116	CbGbCtD
Linagliptin—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0368	0.1	CbGbCtD
Linagliptin—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0342	0.0931	CbGbCtD
Linagliptin—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0262	0.0714	CbGbCtD
Linagliptin—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0244	0.0665	CbGbCtD
Linagliptin—ABCB1—Etoposide—peripheral nervous system neoplasm	0.024	0.0654	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0164	0.0446	CbGbCtD
Linagliptin—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0157	0.0428	CbGbCtD
Linagliptin—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0144	0.0392	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00981	0.0267	CbGbCtD
Linagliptin—Blood triglycerides increased—Isotretinoin—peripheral nervous system neoplasm	0.00231	0.0167	CcSEcCtD
Linagliptin—Hyperlipidaemia—Tretinoin—peripheral nervous system neoplasm	0.0021	0.0152	CcSEcCtD
Linagliptin—Hyperlipidaemia—Isotretinoin—peripheral nervous system neoplasm	0.0021	0.0152	CcSEcCtD
Linagliptin—Hypertriglyceridaemia—Alitretinoin—peripheral nervous system neoplasm	0.002	0.0144	CcSEcCtD
Linagliptin—Blood triglycerides increased—Alitretinoin—peripheral nervous system neoplasm	0.00175	0.0127	CcSEcCtD
Linagliptin—Hyperlipidaemia—Alitretinoin—peripheral nervous system neoplasm	0.00159	0.0115	CcSEcCtD
Linagliptin—Skin exfoliation—Tretinoin—peripheral nervous system neoplasm	0.00144	0.0104	CcSEcCtD
Linagliptin—Skin exfoliation—Isotretinoin—peripheral nervous system neoplasm	0.00144	0.0104	CcSEcCtD
Linagliptin—Skin exfoliation—Melphalan—peripheral nervous system neoplasm	0.00142	0.0103	CcSEcCtD
Linagliptin—Diabetes mellitus—Tretinoin—peripheral nervous system neoplasm	0.00126	0.00913	CcSEcCtD
Linagliptin—Diabetes mellitus—Isotretinoin—peripheral nervous system neoplasm	0.00126	0.00913	CcSEcCtD
Linagliptin—Pain in extremity—Tretinoin—peripheral nervous system neoplasm	0.0011	0.00794	CcSEcCtD
Linagliptin—Pain in extremity—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.00794	CcSEcCtD
Linagliptin—Skin exfoliation—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00792	CcSEcCtD
Linagliptin—Nasopharyngitis—Tretinoin—peripheral nervous system neoplasm	0.000981	0.0071	CcSEcCtD
Linagliptin—Nasopharyngitis—Isotretinoin—peripheral nervous system neoplasm	0.000981	0.0071	CcSEcCtD
Linagliptin—Diabetes mellitus—Alitretinoin—peripheral nervous system neoplasm	0.000956	0.00692	CcSEcCtD
Linagliptin—Skin exfoliation—Cisplatin—peripheral nervous system neoplasm	0.000932	0.00674	CcSEcCtD
Linagliptin—Pancreatitis—Isotretinoin—peripheral nervous system neoplasm	0.00093	0.00673	CcSEcCtD
Linagliptin—Pancreatitis—Tretinoin—peripheral nervous system neoplasm	0.00093	0.00673	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Tretinoin—peripheral nervous system neoplasm	0.000882	0.00638	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Isotretinoin—peripheral nervous system neoplasm	0.000882	0.00638	CcSEcCtD
Linagliptin—Weight increased—Topotecan—peripheral nervous system neoplasm	0.00087	0.0063	CcSEcCtD
Linagliptin—Weight increased—Tretinoin—peripheral nervous system neoplasm	0.000863	0.00625	CcSEcCtD
Linagliptin—Weight increased—Isotretinoin—peripheral nervous system neoplasm	0.000863	0.00625	CcSEcCtD
Linagliptin—Skin exfoliation—Etoposide—peripheral nervous system neoplasm	0.000854	0.00618	CcSEcCtD
Linagliptin—Infestation NOS—Topotecan—peripheral nervous system neoplasm	0.000853	0.00617	CcSEcCtD
Linagliptin—Infestation—Topotecan—peripheral nervous system neoplasm	0.000853	0.00617	CcSEcCtD
Linagliptin—Infestation NOS—Tretinoin—peripheral nervous system neoplasm	0.000846	0.00612	CcSEcCtD
Linagliptin—Infestation—Tretinoin—peripheral nervous system neoplasm	0.000846	0.00612	CcSEcCtD
Linagliptin—Infestation NOS—Isotretinoin—peripheral nervous system neoplasm	0.000846	0.00612	CcSEcCtD
Linagliptin—Infestation—Isotretinoin—peripheral nervous system neoplasm	0.000846	0.00612	CcSEcCtD
Linagliptin—Pain in extremity—Alitretinoin—peripheral nervous system neoplasm	0.000832	0.00602	CcSEcCtD
Linagliptin—Urinary tract infection—Isotretinoin—peripheral nervous system neoplasm	0.000822	0.00595	CcSEcCtD
Linagliptin—Urinary tract infection—Tretinoin—peripheral nervous system neoplasm	0.000822	0.00595	CcSEcCtD
Linagliptin—Pain in extremity—Vincristine—peripheral nervous system neoplasm	0.000801	0.0058	CcSEcCtD
Linagliptin—Nasopharyngitis—Alitretinoin—peripheral nervous system neoplasm	0.000744	0.00538	CcSEcCtD
Linagliptin—Pancreatitis—Alitretinoin—peripheral nervous system neoplasm	0.000705	0.0051	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—peripheral nervous system neoplasm	0.000696	0.00503	CcSEcCtD
Linagliptin—Immune system disorder—Topotecan—peripheral nervous system neoplasm	0.000691	0.005	CcSEcCtD
Linagliptin—Mediastinal disorder—Topotecan—peripheral nervous system neoplasm	0.00069	0.00499	CcSEcCtD
Linagliptin—Immune system disorder—Melphalan—peripheral nervous system neoplasm	0.000677	0.0049	CcSEcCtD
Linagliptin—Mediastinal disorder—Melphalan—peripheral nervous system neoplasm	0.000675	0.00489	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Alitretinoin—peripheral nervous system neoplasm	0.000668	0.00483	CcSEcCtD
Linagliptin—Malnutrition—Topotecan—peripheral nervous system neoplasm	0.000666	0.00482	CcSEcCtD
Linagliptin—Malnutrition—Tretinoin—peripheral nervous system neoplasm	0.000661	0.00478	CcSEcCtD
Linagliptin—Malnutrition—Isotretinoin—peripheral nervous system neoplasm	0.000661	0.00478	CcSEcCtD
Linagliptin—Weight increased—Alitretinoin—peripheral nervous system neoplasm	0.000654	0.00473	CcSEcCtD
Linagliptin—Back pain—Topotecan—peripheral nervous system neoplasm	0.000644	0.00466	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—peripheral nervous system neoplasm	0.000644	0.00466	CcSEcCtD
Linagliptin—Infestation NOS—Alitretinoin—peripheral nervous system neoplasm	0.000641	0.00464	CcSEcCtD
Linagliptin—Infestation—Alitretinoin—peripheral nervous system neoplasm	0.000641	0.00464	CcSEcCtD
Linagliptin—Back pain—Tretinoin—peripheral nervous system neoplasm	0.000639	0.00463	CcSEcCtD
Linagliptin—Back pain—Isotretinoin—peripheral nervous system neoplasm	0.000639	0.00463	CcSEcCtD
Linagliptin—Nasopharyngitis—Cisplatin—peripheral nervous system neoplasm	0.000634	0.00459	CcSEcCtD
Linagliptin—Urinary tract infection—Alitretinoin—peripheral nervous system neoplasm	0.000623	0.00451	CcSEcCtD
Linagliptin—Angioedema—Topotecan—peripheral nervous system neoplasm	0.000609	0.00441	CcSEcCtD
Linagliptin—Pancreatitis—Cisplatin—peripheral nervous system neoplasm	0.000601	0.00435	CcSEcCtD
Linagliptin—Cough—Topotecan—peripheral nervous system neoplasm	0.000581	0.00421	CcSEcCtD
Linagliptin—Cough—Tretinoin—peripheral nervous system neoplasm	0.000577	0.00417	CcSEcCtD
Linagliptin—Cough—Isotretinoin—peripheral nervous system neoplasm	0.000577	0.00417	CcSEcCtD
Linagliptin—Cough—Melphalan—peripheral nervous system neoplasm	0.000569	0.00412	CcSEcCtD
Linagliptin—Myalgia—Topotecan—peripheral nervous system neoplasm	0.000567	0.0041	CcSEcCtD
Linagliptin—Arthralgia—Topotecan—peripheral nervous system neoplasm	0.000567	0.0041	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—peripheral nervous system neoplasm	0.000563	0.00408	CcSEcCtD
Linagliptin—Arthralgia—Tretinoin—peripheral nervous system neoplasm	0.000563	0.00407	CcSEcCtD
Linagliptin—Arthralgia—Isotretinoin—peripheral nervous system neoplasm	0.000563	0.00407	CcSEcCtD
Linagliptin—Myalgia—Isotretinoin—peripheral nervous system neoplasm	0.000563	0.00407	CcSEcCtD
Linagliptin—Myalgia—Tretinoin—peripheral nervous system neoplasm	0.000563	0.00407	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.000559	0.00404	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.000559	0.00404	CcSEcCtD
Linagliptin—Myalgia—Melphalan—peripheral nervous system neoplasm	0.000555	0.00402	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.000552	0.00399	CcSEcCtD
Linagliptin—Anaphylactic shock—Topotecan—peripheral nervous system neoplasm	0.000544	0.00393	CcSEcCtD
Linagliptin—Infection—Topotecan—peripheral nervous system neoplasm	0.00054	0.00391	CcSEcCtD
Linagliptin—Anaphylactic shock—Tretinoin—peripheral nervous system neoplasm	0.000539	0.0039	CcSEcCtD
Linagliptin—Anaphylactic shock—Isotretinoin—peripheral nervous system neoplasm	0.000539	0.0039	CcSEcCtD
Linagliptin—Infection—Tretinoin—peripheral nervous system neoplasm	0.000536	0.00388	CcSEcCtD
Linagliptin—Infection—Isotretinoin—peripheral nervous system neoplasm	0.000536	0.00388	CcSEcCtD
Linagliptin—Anaphylactic shock—Melphalan—peripheral nervous system neoplasm	0.000532	0.00385	CcSEcCtD
Linagliptin—Infection—Melphalan—peripheral nervous system neoplasm	0.000529	0.00383	CcSEcCtD
Linagliptin—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.000528	0.00382	CcSEcCtD
Linagliptin—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.000524	0.00379	CcSEcCtD
Linagliptin—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.000524	0.00379	CcSEcCtD
Linagliptin—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.000517	0.00374	CcSEcCtD
Linagliptin—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.000501	0.00362	CcSEcCtD
Linagliptin—Infestation—Etoposide—peripheral nervous system neoplasm	0.0005	0.00362	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—peripheral nervous system neoplasm	0.0005	0.00362	CcSEcCtD
Linagliptin—Mediastinal disorder—Vincristine—peripheral nervous system neoplasm	0.0005	0.00362	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.000495	0.00358	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.000491	0.00356	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000491	0.00356	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.000485	0.00351	CcSEcCtD
Linagliptin—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.000485	0.00351	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—peripheral nervous system neoplasm	0.000479	0.00346	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000469	0.0034	CcSEcCtD
Linagliptin—Back pain—Vincristine—peripheral nervous system neoplasm	0.000467	0.00338	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000466	0.00337	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000466	0.00337	CcSEcCtD
Linagliptin—Constipation—Topotecan—peripheral nervous system neoplasm	0.000465	0.00336	CcSEcCtD
Linagliptin—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000461	0.00334	CcSEcCtD
Linagliptin—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000461	0.00334	CcSEcCtD
Linagliptin—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.00046	0.00333	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.00046	0.00333	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—peripheral nervous system neoplasm	0.000443	0.0032	CcSEcCtD
Linagliptin—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.000443	0.0032	CcSEcCtD
Linagliptin—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000442	0.0032	CcSEcCtD
Linagliptin—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000438	0.00317	CcSEcCtD
Linagliptin—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000437	0.00316	CcSEcCtD
Linagliptin—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000432	0.00313	CcSEcCtD
Linagliptin—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000429	0.0031	CcSEcCtD
Linagliptin—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000429	0.0031	CcSEcCtD
Linagliptin—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000427	0.00309	CcSEcCtD
Linagliptin—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000426	0.00309	CcSEcCtD
Linagliptin—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.000426	0.00309	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.00306	CcSEcCtD
Linagliptin—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000423	0.00306	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—peripheral nervous system neoplasm	0.000418	0.00303	CcSEcCtD
Linagliptin—Myalgia—Vincristine—peripheral nervous system neoplasm	0.000411	0.00297	CcSEcCtD
Linagliptin—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000409	0.00296	CcSEcCtD
Linagliptin—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000406	0.00294	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000406	0.00294	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000405	0.00293	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000402	0.00291	CcSEcCtD
Linagliptin—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000401	0.0029	CcSEcCtD
Linagliptin—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000397	0.00288	CcSEcCtD
Linagliptin—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000397	0.00288	CcSEcCtD
Linagliptin—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000397	0.00287	CcSEcCtD
Linagliptin—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000394	0.00285	CcSEcCtD
Linagliptin—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000392	0.00284	CcSEcCtD
Linagliptin—Infection—Vincristine—peripheral nervous system neoplasm	0.000391	0.00283	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.0028	CcSEcCtD
Linagliptin—Back pain—Etoposide—peripheral nervous system neoplasm	0.000378	0.00274	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000373	0.0027	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000372	0.0027	CcSEcCtD
Linagliptin—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000372	0.00269	CcSEcCtD
Linagliptin—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000369	0.00267	CcSEcCtD
Linagliptin—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000369	0.00267	CcSEcCtD
Linagliptin—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000364	0.00264	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000364	0.00263	CcSEcCtD
Linagliptin—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000363	0.00263	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000361	0.00261	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000359	0.0026	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000353	0.00255	CcSEcCtD
Linagliptin—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00035	0.00253	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000348	0.00252	CcSEcCtD
Linagliptin—Infection—Cisplatin—peripheral nervous system neoplasm	0.000346	0.0025	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.0025	CcSEcCtD
Linagliptin—Rash—Topotecan—peripheral nervous system neoplasm	0.000343	0.00248	CcSEcCtD
Linagliptin—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000343	0.00248	CcSEcCtD
Linagliptin—Cough—Etoposide—peripheral nervous system neoplasm	0.000341	0.00247	CcSEcCtD
Linagliptin—Headache—Topotecan—peripheral nervous system neoplasm	0.000341	0.00246	CcSEcCtD
Linagliptin—Rash—Tretinoin—peripheral nervous system neoplasm	0.00034	0.00246	CcSEcCtD
Linagliptin—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00034	0.00246	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00034	0.00246	CcSEcCtD
Linagliptin—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00034	0.00246	CcSEcCtD
Linagliptin—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00034	0.00246	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000338	0.00245	CcSEcCtD
Linagliptin—Headache—Tretinoin—peripheral nervous system neoplasm	0.000338	0.00245	CcSEcCtD
Linagliptin—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000338	0.00245	CcSEcCtD
Linagliptin—Constipation—Vincristine—peripheral nervous system neoplasm	0.000337	0.00244	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.00244	CcSEcCtD
Linagliptin—Rash—Melphalan—peripheral nervous system neoplasm	0.000336	0.00243	CcSEcCtD
Linagliptin—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000335	0.00243	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000331	0.00239	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000325	0.00235	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000325	0.00235	CcSEcCtD
Linagliptin—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000325	0.00235	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000319	0.00231	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000317	0.0023	CcSEcCtD
Linagliptin—Infection—Etoposide—peripheral nervous system neoplasm	0.000317	0.00229	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00031	0.00224	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000308	0.00223	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000302	0.00218	CcSEcCtD
Linagliptin—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000301	0.00218	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.00218	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000301	0.00218	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000292	0.00212	CcSEcCtD
Linagliptin—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00029	0.0021	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000286	0.00207	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.00206	CcSEcCtD
Linagliptin—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00028	0.00203	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00028	0.00203	CcSEcCtD
Linagliptin—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00028	0.00202	CcSEcCtD
Linagliptin—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000278	0.00201	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000275	0.00199	CcSEcCtD
Linagliptin—Constipation—Etoposide—peripheral nervous system neoplasm	0.000273	0.00197	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000273	0.00197	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00027	0.00196	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00027	0.00195	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.00192	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.00188	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.00188	CcSEcCtD
Linagliptin—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000258	0.00187	CcSEcCtD
Linagliptin—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000258	0.00186	CcSEcCtD
Linagliptin—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000257	0.00186	CcSEcCtD
Linagliptin—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000256	0.00185	CcSEcCtD
Linagliptin—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000254	0.00183	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.00183	CcSEcCtD
Linagliptin—Rash—Vincristine—peripheral nervous system neoplasm	0.000248	0.0018	CcSEcCtD
Linagliptin—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000248	0.0018	CcSEcCtD
Linagliptin—Headache—Vincristine—peripheral nervous system neoplasm	0.000247	0.00179	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000238	0.00172	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000235	0.0017	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000227	0.00165	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000227	0.00164	CcSEcCtD
Linagliptin—Rash—Cisplatin—peripheral nervous system neoplasm	0.00022	0.00159	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000219	0.00159	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000219	0.00159	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000218	0.00158	CcSEcCtD
Linagliptin—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00153	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.00152	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.00152	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.00147	CcSEcCtD
Linagliptin—Rash—Etoposide—peripheral nervous system neoplasm	0.000201	0.00146	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000201	0.00145	CcSEcCtD
Linagliptin—Headache—Etoposide—peripheral nervous system neoplasm	0.0002	0.00145	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00142	CcSEcCtD
Linagliptin—Cough—Epirubicin—peripheral nervous system neoplasm	0.000191	0.00138	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000187	0.00135	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000187	0.00135	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000185	0.00134	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000179	0.00129	CcSEcCtD
Linagliptin—Infection—Epirubicin—peripheral nervous system neoplasm	0.000178	0.00129	CcSEcCtD
Linagliptin—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.00128	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000174	0.00126	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.00125	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.00125	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.00124	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.0012	CcSEcCtD
Linagliptin—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.00119	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000163	0.00118	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.00116	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000154	0.00112	CcSEcCtD
Linagliptin—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000153	0.00111	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.00109	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.00103	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000142	0.00103	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.00102	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000954	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000951	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000886	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000882	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000819	CcSEcCtD
Linagliptin—Rash—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000816	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000815	CcSEcCtD
Linagliptin—Headache—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000811	CcSEcCtD
Linagliptin—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000755	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000754	CcSEcCtD
Linagliptin—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.00075	CcSEcCtD
